FOLD
Amicus Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.55B
P/E Ratio
—
EPS
$-0.09
Beta
0.48
52W High
$14.50
52W Low
$5.51
50-Day MA
$14.40
200-Day MA
$10.88
Dividend Yield
—
Profit Margin
-4.28%
Forward P/E
30.49
PEG Ratio
-0.18
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Fundamentals
| Revenue (TTM) | $634.21M |
| Gross Profit (TTM) | $561.28M |
| EBITDA | $41.95M |
| Operating Margin | 8.61% |
| Return on Equity | -11.60% |
| Return on Assets | 2.49% |
| Revenue/Share (TTM) | $2.06 |
| Book Value | $0.88 |
| Price-to-Book | 16.59 |
| Price-to-Sales (TTM) | 7.17 |
| EV/Revenue | 7.41 |
| EV/EBITDA | 87.32 |
| Quarterly Earnings Growth (YoY) | -95.50% |
| Quarterly Revenue Growth (YoY) | 23.70% |
| Shares Outstanding | $314.00M |
| Float | $311.44M |
| % Insiders | 0.69% |
| % Institutions | 104.72% |
Historical Volatility
HV 10-Day
1.16%
HV 20-Day
1.44%
HV 30-Day
1.67%
HV 60-Day
1.74%
HV Rank
1.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($14.50 target)
7
HoldData last updated: 4/29/2026